Literature DB >> 25659981

Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder.

Stephen M Stahl.   

Abstract

Flibanserin is a novel multifunctional serotonin agonist and antagonist (MSAA) that improves sexual functioning in premenopausal women who suffer from reduced sexual interest and desire.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25659981     DOI： 10.1017/S1092852914000832

Source DB:  PubMed          Journal:  CNS Spectr        ISSN： 1092-8529            Impact factor:   3.790


  10 in total

1.  Sexual dysfunction in 2015: Recovering sex drive in women - progress and opportunities.

Authors:  Rossella E Nappi; Francesca Albani
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

2.  Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

Authors:  Clayton English; Anne Muhleisen; Jose A Rey
Journal:  P T       Date:  2017-04

3.  Treatment of Hypoactive Sexual Desire Disorder Among Women: General Considerations and Pharmacological Options.

Authors:  Gabriela S Pachano Pesantez; Anita H Clayton
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

4.  Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin.

Authors:  Usama A Fahmy; Osama A A Ahmed; Shaimaa M Badr-Eldin; Hibah M Aldawsari; Solomon Z Okbazghi; Zuhier A Awan; Muhammed A Bakhrebah; Mohammad N Alomary; Wesam H Abdulaal; Carlos Medina; Nabil A Alhakamy
Journal:  Int J Nanomedicine       Date:  2020-07-24

Review 5.  Flibanserin: First Global Approval.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2015-10       Impact factor: 9.546

6.  Flibanserin: A controversial drug for female hypoactive sexual desire disorder.

Authors:  Rashmi Baid; Rakesh Agarwal
Journal:  Ind Psychiatry J       Date:  2018 Jan-Jun

7.  Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile.

Authors:  Jacek Stefanowicz; Tomasz Słowiński; Martyna Z Wróbel; Grzegorz Ślifirski; Maciej Dawidowski; Zdzisława Stefanowicz; Magdalena Jastrzębska-Więsek; Anna Partyka; Anna Wesołowska; Jadwiga Turło
Journal:  Med Chem Res       Date:  2018-06-22       Impact factor: 1.965

8.  Route to Benzimidazol-2-ones via Decarbonylative Ring Contraction of Quinoxalinediones: Application to the Synthesis of Flibanserin, A Drug for Treating Hypoactive Sexual Desire Disorder in Women and Marine Natural Product Hunanamycin Analogue.

Authors:  Rahul D Shingare; Akshay S Kulkarni; Revannath L Sutar; D Srinivasa Reddy
Journal:  ACS Omega       Date:  2017-08-29

9.  Flibanserin: Approval of a controversial drug for a controversial disorder.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2015 Jul-Sep       Impact factor: 1.759

10.  Next-day residual effects of flibanserin on simulated driving performance in premenopausal women.

Authors:  Gary G Kay; Thomas Hochadel; Eric Sicard; Karthi K Natarajan; Noel N Kim
Journal:  Hum Psychopharmacol       Date:  2017-05-31       Impact factor: 1.672
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.